50 results
Phase I:-To determine the maximum tolerated dose (MTD) and recommended phase II dose level (RDL) of Bortezomib administered once weekly, and of Lenalidomide administered for 3 weeks when combined with Dexamethasone in a 28-days schedule.Phase II:-To…
Does dexamethason reduce the levels of plasma inflammatory proteins in patients undergoing coronary artery bypass graft (CABG) surgery who have a normal or disturbed ejection fraction such that proapoptotic pathways are inhibited?Does a…
The objective of this study is to test the hypothesis that in patients with inflammatory neuropathies and conduction blocks, corticosteroid treatment leads to:1. Hyperpolarization and reduced excitability of motor axons. 2. An increase of the number…
Although these products have been used extensively in patients, the effect of these medications on experimental pain sensation has never been investigated. There is little knowledge about any direct effect of these medications on pain perception. In…
To determine the antileukemic activity of combination chemotherapy including bortezomib as reinduction therapy in childhood relapsed/refractory ALL.
PrimaryTo assess the extended overall response rates of orally administered TKI258, at 500 mg/day, on a five days on and two days off dosing schedule, in groups of patients with relapsed or refractory multiple myeloma who are* with t(4;14)…
The primary objective of this study is to determine if there is an improvement in progression-free survival(PFS) when siltuximab is added to VELCADE* (bortezomib) and dexamethasone in subjects with relapsedor refractory multiple myeloma.The…
(1) Determination of the effect of dexamethasone on the biodistribution and kinetics of [11C]TMZ in GBM patients. (2) The effect of DXM on CBF. If there is an effect of DXM on CBF: (3) The effect of blood flow in the brain on [11C]TMZ uptake.
To establish the safety profile of daratumumab when given in combination with bortezomib and dexamethasone in subjects with relapsed or refractory MM
To compare progression-free survival in subjects with relapsed multiple myeloma who are receiving CRd vs PFS in subjects receiving Rd alone.
The primary objective is to compare PFS after treatment with tabalumab, bortezomib, anddexamethasone to that of placebo, bortezomib, and dexamethasone in patients with relapsed/refractory MM.Secondary objectives will include comparison of treatment…
Evaluation of the effect of salvage therapy with R-DHAP followed by reduced-intensity conditioning and allogeneic stem cell transplantation from a sibling or unrelated donor
GACHE aims to evaluate the effect on morbidity and mortality of early adjuvantcorticosteroids (dexamethasone) in the treatment of adult patients with HSVE. The major motivation for this trial is the extremely unsatisfactory outcome of patients…
To assess whether a single shot of dexamethasone reduces postoperative pain, and reduces the time children need to start with drinking and eating.
This study examines if there are therapeutic benefits over injecting dexamethason into the temporomandibular joint after arthrocentesis with patients with ostheoarthritis.
Primary Objective(s)Phase I (completed)The primary objective of the Phase I portion of the study is to determine the maximum tolerated dose (MTD) of the combination of melflufen and dexamethasone in patients with relapsed/refractory multiple myeloma…
* To establish the safety profile of daratumumab when given in combination with lenalidomide and dexamethasone in subjects with relapsed or relapsed and refractory MM
Primary: To determine the optimal dose/recommended dose (RD) of pre-medication dexamethasone around docetaxel infusion.Secondary: * Does a dose reduction of prophylactic dexamethasone around the docetaxel infusion decrease the body*s metabolic…
In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antiemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed CINV induced by non-AC based…
We plan to conduct a large, pragmatic, multicentre, randomised non-inferiority trial to determine whether the use of intraoperative dexamethasone, a widely used antiemetic in perioperative medicine, is associated with an unacceptable increased risk…